Physician profile
Stephen Goldfarb
NPI 1497755177
$4,939.36
in general payments reported to CMS, 2019-2025
32 companies · $609 in 2025
The $609 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $609 · 2020: $277 · 2021: $1,795 · 2022: $596 · 2023: $490 · 2024: $563 · 2025: $609.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $985 · Honoraria: $350 · Travel and Lodging: $327.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $985.38 |
| Honoraria | $350.00 |
| Travel and Lodging | $326.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $1,300.00 | 2021 | |
| Beigene USA, INC. | $525.00 | 2022 | |
| Genzyme Corporation | $420.00 | 2021-2025 | |
| Athenex Pharmaceutical Division, LLC | $405.03 | 2019 | |
| Regeneron Pharmaceuticals, INC. | $350.00 | 2025 | Lynozyfic |
| Pharmacosmos Therapeutics INC. | $326.88 | 2023 | Monoferric |
| Incyte Corporation | $272.64 | 2020-2024 | Jakafi |
| Gilead Sciences, INC. | $131.31 | 2021-2025 | Trodelvy |
| Exelixis INC. | $116.61 | 2019-2025 | Cabometyx |
| Tactile Systems Technology INC | $112.83 | 2022-2024 | Entre Plus, Flexitouch Plus |
| Kite Pharma, INC. | $101.45 | 2019-2025 | Yescarta |
| Novartis Pharmaceuticals Corporation | $99.71 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $82.28 | 2024 | Keytruda, Lynparza |
| Janssen Biotech, INC. | $72.36 | 2021-2025 | Rybrevant |
| Pfizer INC. | $71.56 | 2021-2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $71.23 | 2023-2024 | Reblozyl, Pomalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.63 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $54.90 | 2019-2024 | Fruzaqla |
| Astrazeneca Pharmaceuticals LP | $43.92 | 2022-2025 | |
| Rigel Pharmaceuticals, INC. | $43.26 | 2024 | Tavalisse, Rezlidhia |
| Sobi, INC | $40.55 | 2024 | |
| Aveo Pharmaceuticals, INC. | $36.60 | 2024 | |
| Celltrion USA INC. | $33.67 | 2023 | Vegzelma |
| Bayer Healthcare Pharmaceuticals INC. | $27.04 | 2020 | |
| Pharmacyclics LLC, An Abbvie Company | $23.97 | 2021 | |
| Eisai INC. | $19.29 | 2019 | |
| Daiichi Sankyo INC. | $17.98 | 2024 | Enhertu |
| Beone Medicines USA, INC. | $17.81 | 2025 | Tevimbra |
| Genmab U.S., INC. | $17.52 | 2025 | Epkinly |
| Siemens Medical Solutions USA, INC. | $16.84 | 2021 | |
| Sirtex Medical INC | $16.43 | 2024 | Sir-Spheres Microspheres |
| Dova Pharmaceuticals | $14.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Goldfarb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.